Performance of commercially available SmartWatch-based electrocardiography to identify atrial fibrillation during exercise testing: the WATCH-ECG study

Performance of commercially available SmartWatch-based electrocardiography to identify atrial fibrillation during exercise testing: the WATCH-ECG study - WATCH-ECG study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50030

Enrollment

Registered

2019-03-11

Start date

2019-07-10

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Afib irregular heart rhythm

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years of age or older; - Willing and able to provide written informed consent; - Scheduled for routine exercise testing, irrespective of indication; - Willing to undergo an additional ECG recording using the Apple Watch.

Exclusion criteria

Exclusion criteria: - Unwilling or unable to provide written informed consent; - Fall-prone patients during exercise testing, e.g. due to limited mobility, visual or cognitive impairment.

Design outcomes

Primary

Measure	Time frame
Main study endpoint This study is designed to assess diagnostic accuracy, as defined by sensitivity and specificity, of a commercially available heart rate monitor (Apple Watch) in detecting AF during tachycardia. Details of the device are provided in this chapter.	—

Secondary

Measure	Time frame
None.	—

Countries

Netherlands

Outcome results